RetiSpec
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | - | ||
$100k | Seed | ||
N/A | N/A | Seed | |
N/A | Spinout | ||
N/A | $250k | Seed | |
* | N/A | Grant | |
* | N/A | Early VC | |
* | $10.0m | Series A | |
Total Funding | €9.4m |
Recent News about RetiSpec
EditRetiSpec is a medical imaging company focused on the early detection of disease biomarkers in the eye, particularly for Alzheimer's disease. The company operates in the healthcare and medical technology market, serving clinics, hospitals, and research institutions. RetiSpec's core product is a retinal scanner that integrates both software and hardware components, which can be applied to existing retinal cameras commonly found in medical offices. The technology uses computer vision and machine learning algorithms to detect unique signatures of biomarkers within seconds, enabling timely and specific therapeutic interventions. This early detection tool aims to slow or even prevent the progression of diseases, thereby improving patient outcomes and reducing healthcare costs. RetiSpec generates revenue through the sale and licensing of its retinal scanning technology to medical facilities and research organizations. The company also collaborates with partners for clinical studies and further development of its technology.
Keywords: Alzheimer's, retinal scanner, biomarkers, early detection, medical imaging, computer vision, machine learning, healthcare, diagnostic tool, therapeutic interventions.